Funding round
Colossal Series B
Colossal, which works in genome editing and de-extinction services in Austin, raised $150M in a Series B round announced on 31 Jan 2023, led by United States Innovative Technology and Breyer Capital. 9 firms took part. It is Colossal's third venture round on record; the one before was a Series A in Mar 2022.
$150M
Amount raised
Not disclosed
Post-money valuation
9
Investors
2 leads
Valuation
What this round says about the price
Colossal did not disclose a valuation in this round. It came 10 months after Colossal's Series A. It is 35% of the $425M Colossal has raised in the venture rounds on record. Colossal raised again 24 months later: a Series C round of $200M in Jan 2025, at $10.20B post-money.
Colossal's funding rounds
Colossal has 4 venture rounds on record and 1 other deal. This one is highlighted.
- Seed 1 May 2021, led by Thomas Tull $15M
- Series A 9 Mar 2022, led by At One Ventures $60M
- Grant not a venture round 1 Oct 2022 amount not disclosed
- Series B this round 31 Jan 2023, led by United States Innovative Technology and Breyer Capital $150M
- Series C 17 Jan 2025, led by TWG Global $200M$10.20B post-money
Investors
Who put money in
United States Innovative Technology and Breyer Capital led the round with 7 other firms.
Lead investors
- backs 20 venture-backed companies new investor
- Breyer Capital backs 85 venture-backed companies new investor
Also in the round
- backs 11 venture-backed companies new investor
- backs 24 venture-backed companies new investor
- In-Q-Tel backs 97 venture-backed companies new investor
- Animoca Brands new investor
- backs 22 venture-backed companies new investor
- backs 45 venture-backed companies new investor
- backs 32 venture-backed companies new investor
Use of proceeds
What the money is for
According to the announcement, the money goes to product development.
- Product development
Comparable rounds
How it compares
67 Series B rounds in Biotechnology within a year either side disclosed an amount; the median was $60M, and this round was 2.5 times the median. The closest in time, other companies' Series B rounds in Biotechnology:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Biotechnology | 5 Jan 2023 | $175M | not disclosed | Canada Pension Plan Investment Board |
| Biotechnology | 5 Jan 2023 | $85M | not disclosed | Arix Bioscience and 5AM Ventures |
| Biotechnology | 26 Jan 2023 | $49M | not disclosed | Pfizer Ventures and Earlybird |
| Biotechnology | 19 Jan 2023 | $10M | not disclosed | not named |
| Biotechnology | 17 Jan 2023 | $9.0M | not disclosed | Adjuvant Capital and bioMérieux |
| Biotechnology | 19 Jan 2023 | $7.5M | not disclosed | Claris Ventures |
| Biotechnology | 13 Feb 2023 | $77M | not disclosed | The Column Group |
| Enveda Biotechnology | 21 Dec 2022 | $68M | not disclosed | Dimension |
Sources
Where this comes from
Reported by 4 sources.
Questions
Frequently asked
How much did Colossal raise in its Series B round?
Colossal raised $150M in its Series B round, announced in Jan 2023.
Who led Colossal's Series B round?
United States Innovative Technology and Breyer Capital led it, with WestRiver Group, Animal Capital, In-Q-Tel, Animoca Brands and PEAK6 and 2 more.
What was Colossal's valuation at the Series B round?
It was not disclosed.
How does it compare with other Series B rounds in Biotechnology?
67 Series B rounds in Biotechnology within a year either side disclosed an amount; the median was $60M, and this round was 2.5 times the median.
Did Colossal raise again after this round?
Yes: a Series C round in Jan 2025 of $200M at $10.20B post-money.